Compare Summit Therapeutics Inc (SMMT) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Warner Music Group Corp — how do they compare? Summit Therapeutics Inc trades at $17.54 (market cap $13.71B), while Warner Music Group Corp trades at $28.74 (market cap $15.12B). The key difference: Summit Therapeutics Inc and Warner Music Group Corp are close in size by market cap, and Warner Music Group Corp pays a 2.77% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Warner Music Group Corp for 96 Days on average.
| SMMT | WMG | |
|---|---|---|
Market Cap | $13.71B | $15.12B |
Volume | 6,173,057 | 2,966,414 |
Sector | Health | Media |
52-Week High | $26.38 | $34.72 |
52-Week Low | $12.43 | $23.65 |
Typical Hold Time | 16 Days | 96 Days |
Enterprise Value | $13.04B | $19.42B |
Dividend Yield | — | 2.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
WMG trades at $28.875, up 2.54% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.38, beating expectations, and has a strong analyst consensus of 'Buy' with a $39.50 price target. Recent news highlights AI partnerships and licensing renewals as growth catalysts.
Outlook remains positive due to streaming growth and AI initiatives, but risks include competitive pressures and margin volatility. The stock offers upside potential from current levels if execution continues, though investor caution is warranted near-term given elevated RSI levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
